IQIRVO

Product Overview

About IQIRVO

IQIRVO is a prescription medication containing the active ingredient Elafibranor, a peroxisome proliferator-activated receptor alpha (PPARα) and gamma (PPARγ) dual agonist. It is used to treat primary biliary cholangitis (PBC), a chronic liver disease characterized by progressive destruction of the bile ducts within the liver.

Key Benefits & Uses

• Treatment of primary biliary cholangitis (PBC) to slow disease progression and improve liver function.
• Management of elevated alkaline phosphatase levels associated with PBC.
• Improvement of pruritus (itching) and fatigue in patients with PBC.

Active Ingredient & Action

Elafibranor, the active ingredient in IQIRVO, works by activating PPARα and PPARγ receptors, which play a crucial role in regulating lipid metabolism, inflammation, and fibrosis in the liver. By activating these receptors, Elafibranor helps to reduce liver inflammation, improve bile flow, and slow disease progression in patients with PBC.

Important Notes

IQIRVO is available only by prescription and should be used under the guidance of a healthcare professional. It is essential to follow the recommended dosage and treatment schedule to ensure optimal efficacy and minimize potential side effects. Patients with a history of liver disease, kidney disease, or other medical conditions should consult their doctor before starting treatment with IQIRVO.